



# MATERIAL SAFETY DATA SHEET

Revision date: 02-Jan-2007

Version: 1.1

Page 1 of 6

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

**Pfizer Inc**  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-212-573-2222

**Pfizer Ltd**  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161

Emergency telephone number:  
CHEMTREC (24 hours): 1-800-424-9300

Emergency telephone number:  
ChemSafe (24 hours): +44 (0)208 762 8322

### Material Name: Nicergoline Soluble Tablets

**Trade Name:** Sermion 30 mg Soluble Tablets  
**Chemical Family:** Mixture  
**Intended Use:** Pharmaceutical product used as cognition activator

## 2. COMPOSITION/INFORMATION ON INGREDIENTS

### Hazardous

Ingredient	CAS Number	EU EINECS List	%
Nicergoline	27848-84-6	248-694-6	30 mg***
Tartaric acid	87-69-4	201-766-0	*

Ingredient	CAS Number	EU EINECS List	%
Mannitol	69-65-8	200-711-8	*
Polyethylene glycol	25322-68-3	Not listed	*
Sodium bicarbonate	144-55-8	205-633-8	*
Cherry flavor, artificial	NOT ASSIGNED	Not listed	*
Aspartame	22839-47-0	245-261-3	*
Leucine	61-90-5	200-522-0	*

### Additional Information:

\* Proprietary  
\*\*\* per tablet/capsule/lozenge/suppository  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

## 3. HAZARDS IDENTIFICATION

**Appearance:** White tablets

**Statement of Hazard:** Non-hazardous in accordance with international standards for workplace safety.

### Additional Hazard Information:

**Short Term:** May cause drowsiness, insomnia, nervousness, and dizziness.  
**Known Clinical Effects:** Ingestion of this material may cause effects similar to those seen in clinical use including hypotension (low blood pressure), dizziness, headache and drowsiness. Adverse effects associated with the therapeutic use include skin rash and gastrointestinal disturbances.  
**EU Indication of danger:** Not classified

## MATERIAL SAFETY DATA SHEET

Material Name: Nicergoline Soluble Tablets  
Revision date: 02-Jan-2007

Page 2 of 6  
Version: 1.1

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 4. FIRST AID MEASURES

**Eye Contact:** If irritation occurs or persists, get medical attention. Flush eyes with water as a precaution

**Skin Contact:** Wash skin with soap and water. If irritation occurs or persists, get medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

**Hazardous Combustion Products:** Emits toxic fumes of carbon monoxide, carbon dioxide, oxides of nitrogen and bromine-containing compounds

**Fire Fighting Procedures:** During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

**Fire / Explosion Hazards:** Not applicable

### 6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Measures for Environmental Protections:** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

**General Handling:** If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes.

## MATERIAL SAFETY DATA SHEET

Material Name: Nicergoline Soluble Tablets  
Revision date: 02-Jan-2007

Page 3 of 6  
Version: 1.1

**Storage Conditions:** Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames.

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

#### Nicergoline

**Pfizer Occupational Exposure Band (OEB):** OEB3 (control exposure to the range of >10ug/m<sup>3</sup> to < 100ug/m<sup>3</sup>)

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. Use process containment, local exhaust ventilation, or other engineering controls to maintain airborne levels within the OEB range.

#### Personal Protective Equipment:

**Hands:** Not required for the normal use of this product. Wear protective gloves when working with large quantities.

**Eyes:** Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.

**Skin:** Not required for the normal use of this product. Wear protective clothing when working with large quantities.

**Respiratory protection:** None required under normal conditions of use. If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

### 9. PHYSICAL AND CHEMICAL PROPERTIES:

<b>Physical State:</b>	Tablets	<b>Color:</b>	White
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture

### 10. STABILITY AND REACTIVITY

**Stability:** Stable under normal conditions of use.

**Conditions to Avoid:** Not determined

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers.

### 11. TOXICOLOGICAL INFORMATION

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### Mannitol

Rat	Oral	LD 50	13500	mg/kg
Mouse	Oral	LD 50	22	g/kg

## MATERIAL SAFETY DATA SHEET

Material Name: Nicergoline Soluble Tablets  
Revision date: 02-Jan-2007

Page 4 of 6  
Version: 1.1

### Sodium bicarbonate

Rat Oral LD50 4220 mg/kg  
Mouse Oral LD50 3360 mg/kg  
Rat Inhalation LC50 > 900 mg/m<sup>3</sup>

### Nicergoline

Rat Oral LD 50 1193 mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

### Irritation / Sensitization: (Study Type, Species, Severity)

#### Polyethylene glycol

Eye Irritation Rabbit Mild  
Skin Irritation Rabbit Mild

### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

#### Nicergoline

Embryo / Fetal Development Rat Oral Not teratogenic  
Embryo / Fetal Development Rabbit Fetotoxicity  
Embryo / Fetal Development Rat Intramuscular Not Teratogenic

**Carcinogen Status:** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

## 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

## 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

## 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## 15. REGULATORY INFORMATION

**EU Indication of danger:** Not classified

# MATERIAL SAFETY DATA SHEET

Material Name: Nicergoline Soluble Tablets  
Revision date: 02-Jan-2007

Page 5 of 6  
Version: 1.1

## OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

## Canada - WHMIS: Classifications

### WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

### Nicergoline

Standard for the Uniform Scheduling  
for Drugs and Poisons: Schedule 4

EU EINECS List 248-694-6

### Mannitol

Inventory - United States TSCA - Sect. 8(b) Present

Australia (AICS): Present

EU EINECS List 200-711-8

### Polyethylene glycol

Inventory - United States TSCA - Sect. 8(b) XU

Australia (AICS): Present

### Sodium bicarbonate

Inventory - United States TSCA - Sect. 8(b) Present

Australia (AICS): Present

EU EINECS List 205-633-8

### Aspartame

Inventory - United States TSCA - Sect. 8(b) Present

Australia (AICS): Present

EU EINECS List 245-261-3

### Tartaric acid

Inventory - United States TSCA - Sect. 8(b) Present

Australia (AICS): Present

EU EINECS List 201-766-0

### Leucine

Inventory - United States TSCA - Sect. 8(b) Present

Australia (AICS): Present

EU EINECS List 200-522-0

## 16. OTHER INFORMATION

### Reasons for Revision:

Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard Identification. Updated Section 5 - Fire Fighting Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 9 - Physical and Chemical Properties. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations.

## MATERIAL SAFETY DATA SHEET

Material Name: Nicergoline Soluble Tablets  
Revision date: 02-Jan-2007

Page 6 of 6  
Version: 1.1

---

**Prepared by:**

Toxicology and Hazard Communication  
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

**End of Safety Data Sheet**